Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsAntonio Omuro, MD
Professor AdjunctDownloadHi-Res Photo
About
Copy Link
Titles
Professor Adjunct
Biography
Dr. Omuro is a Professor Adjunct in the department of Neurology at the Yale School of Medicine.
He is the former chief of the Division of Neuro-Oncology and Director of the Yale Brain Tumor Center. He is a graduate and former faculty of the Neuro-Oncology program at Memorial Sloan Kettering Cancer Center in New York. Dr. Omuro is an internationally renowned leader in clinical care and research in the field of brain tumors, having led pivotal research projects and clinical trials to advance the treatment of these difficult cancers.
Dr. Omuro is currently the chair of the Department of Neurology and Neurological Sciences at Stanford University.
Last Updated on July 15, 2024.
Departments & Organizations
- All Institutions
- Developmental Therapeutics
- Pituitary Program
Education & Training
- Fellow
- Memorial Sloan Kettering Cancer Center (2004)
- MD
- Sao Paulo School of Medicine (1995)
Research
Copy Link
Overview
Dr. Omuro is an international leader in the research of brain tumors, having led pivotal research programs and clinical trials to advance the treatment of these difficult cancers.
Medical Research Interests
Central Nervous System Neoplasms; Clinical Trial; Glioblastoma; Meningeal Neoplasms
ORCID
0000-0003-4299-3664
Research at a Glance
Yale Co-Authors
Frequent collaborators of Antonio Omuro's published research.
Publications Timeline
A big-picture view of Antonio Omuro's research output by year.
Research Interests
Research topics Antonio Omuro is interested in exploring.
Sanjay Aneja, MD
MingDe Lin, PhD
Veronica Chiang, MD, FAANS
Tal Zeevi
Alexandria Brackett, MLIS, AHIP, MA
David A. Hafler, MD, FANA, MSc
276Publications
25,739Citations
Central Nervous System Neoplasms
Glioblastoma
Meningeal Neoplasms
Publications
2026
Chapter 41 Chemotherapy for primary central nervous system lymphoma
Therkelsen K, Omuro A. Chapter 41 Chemotherapy for primary central nervous system lymphoma. 2026, 675-692. DOI: 10.1016/b978-0-443-27356-8.00028-0.Peer-Reviewed Original ResearchConceptsCentral nervous systemChemotherapy regimensHigh-dose methotrexate-based chemotherapyChimeric antigen receptor T cellsPrimary central nervous system lymphomaCentral nervous system lymphomaPrimary central nervous systemMethotrexate-based chemotherapyMethotrexate-based regimensMyeloablative chemotherapy regimensImmune checkpoint inhibitorsNervous system lymphomaStem-cell transplantationImmunomodulatory imide drugsCheckpoint inhibitorsSystem lymphomaMaintenance therapyRecurrent diseaseT cellsRandomized studyPoor outcomeRegimensBTK inhibitorsClinical trialsPatient population
2025
CTNI-39. TIRABRUTINIB FOR THE TREATMENT OF RELAPSED OR REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: EFFICACY AND SAFETY FROM THE PHASE II PROSPECT STUDY
Nayak L, Grommes C, Kallam A, Peereboom D, Ambady P, Mendez J, Aregawi D, Sumrall A, Omuro A, Iwamoto F, Dietrich J, Umemura Y, Munker R, Chukwueke U, Schaff L, Prados S, Takazawa A, Aoi A, Batchelor T. CTNI-39. TIRABRUTINIB FOR THE TREATMENT OF RELAPSED OR REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: EFFICACY AND SAFETY FROM THE PHASE II PROSPECT STUDY. Neuro-Oncology 2025, 27: v135-v135. PMCID: PMC12601121, DOI: 10.1093/neuonc/noaf201.0535.Peer-Reviewed Original ResearchConceptsPrimary central nervous system lymphomaDuration of responseProgression-free survivalOverall response rateTreatment-emergent adverse eventsCentral nervous system lymphomaNervous system lymphomaSystem lymphomaData cutoffOverall survivalResponse rateProspective studyTreatment optionsRefractory primary central nervous system lymphomaSecond-generation Bruton's tyrosine kinase inhibitorOpen-label phase II studyMedian duration of responsePhase II prospective studyRare non-Hodgkin lymphomaBruton tyrosine kinase inhibitorComplete response ratePartial response rateMaculo-papular rashNon-Hodgkin's lymphomaPhase II studySignal-Seeking P2R Trial of Proton or IMRT Dose Intensification in GBM: NRG-BN001
Mehta M, Pugh S, Mahajan A, Shih H, Tsien C, Chenevert T, Gilbert M, Omuro A, Aldape K, Teo B, Cao Y, Srinivasan A, Khan O, Huang J, Brown P, Kotecha R, Vempati P, Yeboa D, Won M, Gondi V. Signal-Seeking P2R Trial of Proton or IMRT Dose Intensification in GBM: NRG-BN001. International Journal Of Radiation Oncology • Biology • Physics 2025, 123: 1204. DOI: 10.1016/j.ijrobp.2025.08.068.Peer-Reviewed Original ResearchCitationsConceptsSimultaneous integrated boostProton cohortDose intensificationRPA classMGMT statusProton therapyRandomized trialsHazard ratioHigher grade toxicityNRG Oncology trialsMGMT methylation statusLevel 1 evidenceInterim futility analysisMedian OSMGMT analysisIntegrated boostGrade toxicityBrain irradiationOS improvementPhoton therapyToxicity ratesPathological confirmationSurvival improvementTreatment armsPretreatment characteristicsPhase I/II and window-of-opportunity study of pamiparib and metronomic temozolomide for recurrent isocitrate dehydrogenase mutant gliomas
Schiff D, Ye X, Li J, Ellingson B, Wen P, Walbert T, Campian J, Nabors L, Ozer B, Desai A, Omuro A, Desideri S, Danda N, Grossman S, Bindra R. Phase I/II and window-of-opportunity study of pamiparib and metronomic temozolomide for recurrent isocitrate dehydrogenase mutant gliomas. Neuro-Oncology 2025, 28: 485-494. PMID: 41099363, PMCID: PMC12979031, DOI: 10.1093/neuonc/noaf246.Peer-Reviewed Original ResearchCitationsAltmetricConceptsWindow-of-opportunity studyProgression-free survivalIDH mutant gliomasMutant gliomasPARP inhibitorsIntratumoral pharmacokineticsMedian progression-free survivalProlonged progression-free survivalArm B patientsCumulative hematologic toxicityLow-dose temozolomidePhase II doseActivity of PARP inhibitorsLong-term tolerancePharmacologically active concentrationsNon-enhancing tumorDaily temozolomideII doseMetronomic temozolomideRANO criteriaHematologic toxicityRadiographic responseRecurrent gliomaPartial responseArm AOS04.6.A MULTICENTER RANDOMIZED PHASE II STUDY OF R-MPV-A CHEMOIMMUNOTHERAPY WITH OR WITHOUT LOW-DOSE WHOLE-BRAIN RADIOTHERAPY FOR NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA: NRG/ RTOG 1114
Omuro A, Deangelis L, Polley M, Correa D, Wefel J, Bovi J, Rosenblum M, Corn B, Aneja S, Grommes C, Peereboom D, Lallana E, Werner-Wasik M, Rogers C, Iwamoto F, Yu H, Donnelly E, Struve T, Won M, Mehta M. OS04.6.A MULTICENTER RANDOMIZED PHASE II STUDY OF R-MPV-A CHEMOIMMUNOTHERAPY WITH OR WITHOUT LOW-DOSE WHOLE-BRAIN RADIOTHERAPY FOR NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA: NRG/ RTOG 1114. Neuro-Oncology 2025, 27: iii15-iii16. PMCID: PMC12493833, DOI: 10.1093/neuonc/noaf193.045.Peer-Reviewed Original ResearchConceptsPrimary central nervous system lymphomaProgression-free survivalOverall survivalIntent-to-treatPrimary endpointDose of whole-brain radiotherapyNewly diagnosed primary CNS lymphomaHazard ratioDiagnosed primary CNS lymphomaRisk of severe neurotoxicityCentral nervous system lymphomaLow radiotherapy dosesPrimary CNS lymphomaWhole-brain radiotherapyComplete response rateNervous system lymphomaSingle-arm studyCNS lymphomaRadiotherapy doseSystem lymphomaChemotherapy regimenSalvage treatmentMethotrexate doseMedian ageChemoRTMulticenter randomized phase II study of R-MPV-A chemoimmunotherapy with or without low-dose whole-brain radiotherapy for newly-diagnosed primary CNS lymphoma
Omuro A, DeAngelis L, Polley M, Correa D, Wefel J, Bovi J, Rosenblum M, Corn B, Aneja S, Grommes C, Peereboom D, Lallana E, Werner-Wasik M, Rogers C, Iwamoto F, Yu H, Donnelly E, Struve T, Won M, Mehta M. Multicenter randomized phase II study of R-MPV-A chemoimmunotherapy with or without low-dose whole-brain radiotherapy for newly-diagnosed primary CNS lymphoma. Neuro-Oncology 2025, 28: 371-382. PMID: 41189315, PMCID: PMC12904153, DOI: 10.1093/neuonc/noaf221.Peer-Reviewed Original ResearchCitationsAltmetricConceptsPrimary central nervous system lymphomaProgression-free survivalMulticenter randomized phase II studyWhole-brain radiotherapyOverall survivalIntent-to-treatHazard ratioDose of whole-brain radiotherapyRisk of severe neurotoxicityCentral nervous system lymphomaLow radiotherapy dosesPrimary CNS lymphomaNervous system lymphomaSingle-arm studyDisease controlCNS lymphomaRadiotherapy doseSystem lymphomaPrimary endpointMedian ageChemoRTLow-doseSevere neurotoxicityFollow-upResponse rate88 | TIRABRUTINIB FOR THE TREATMENT OF RELAPSED OR REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: EFFICACY AND SAFETY FROM THE PHASE II PROSPECT STUDY
Nayak L, Grommes C, Kallam A, Peereboom D, Ambady P, Mendez J, Aregawi D, Sumrall A, Omuro A, Iwamoto F, Dietrich J, Umemura Y, Munker R, Chukwueke U, Schaff L, Prados S, Takazawa A, Aoi A, Batchelor T. 88 | TIRABRUTINIB FOR THE TREATMENT OF RELAPSED OR REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: EFFICACY AND SAFETY FROM THE PHASE II PROSPECT STUDY. Hematological Oncology 2025, 43 DOI: 10.1002/hon.70093_88.Peer-Reviewed Original ResearchTirabrutinib for the treatment of relapsed or refractory primary central nervous system lymphoma: Efficacy and safety from the phase II PROSPECT study.
Nayak L, Grommes C, Kallam A, Peereboom D, Ambady P, Mendez J, Aregawi D, Sumrall A, Omuro A, Iwamoto F, Dietrich J, Umemura Y, Munker R, Chukwueke U, Schaff L, Prados S, Takazawa A, Aoi A, Batchelor T. Tirabrutinib for the treatment of relapsed or refractory primary central nervous system lymphoma: Efficacy and safety from the phase II PROSPECT study. Journal Of Clinical Oncology 2025, 43: 2019-2019. DOI: 10.1200/jco.2025.43.16_suppl.2019.Peer-Reviewed Original ResearchCitationsAltmetricConceptsPrimary central nervous system lymphomaTreatment-emergent adverse eventsTreatment-related adverse eventsDuration of responseProgression-free survivalTime to responseMedian duration of responseCentral nervous system lymphomaNervous system lymphomaTyrosine kinase inhibitorsSystem lymphomaOverall survivalResponse rateNeutrophil countProspective studyAdverse eventsTreatment optionsRefractory primary central nervous system lymphomaSecond-generation Bruton's tyrosine kinase inhibitorAggressive form of non-Hodgkin lymphomaOpen-label phase II studyDisease progressionMedian progression-free survivalPhase II prospective studyMedian time to response
2024
Advances in Primary Central Nervous System Lymphoma
Therkelsen K, Omuro A. Advances in Primary Central Nervous System Lymphoma. Current Neurology And Neuroscience Reports 2024, 25: 5. PMID: 39585484, DOI: 10.1007/s11910-024-01389-0.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsOlder patientsPrimary central nervous system lymphomaCAR-T cell treatmentCSF cell-free DNACentral nervous system lymphomaPrimary CNS lymphomaPathway-targeted therapiesNervous system lymphomaLow-dose radiationCell-free DNALong-term outcomesGoal of treatmentDevelopment of therapiesCNS lymphomaPCNSL patientsConsolidation therapyCAR-TSystem lymphomaProspective trialsInitial managementTreatment optionsSalvage optionClinical trialsPatientsNeurocognitive outcomesNIMG-30. DEUTERIUM METABOLIC IMAGING (DMI) SHOWS A STRONG RELATION BETWEEN TUMOR GRADE AND GLUCOSE METABOLISM IN PRIMARY BRAIN TUMORS
Thaw-Poon S, Blondin N, Liu Y, Corbin Z, Baehring J, Omuro A, Moliterno J, Omay S, Fulbright R, de Graaf R, De Feyter H. NIMG-30. DEUTERIUM METABOLIC IMAGING (DMI) SHOWS A STRONG RELATION BETWEEN TUMOR GRADE AND GLUCOSE METABOLISM IN PRIMARY BRAIN TUMORS. Neuro-Oncology 2024, 26: viii201-viii201. PMCID: PMC11553074, DOI: 10.1093/neuonc/noae165.0795.Peer-Reviewed Original ResearchConceptsGrade 2 lesionsTumor gradeDeuterium metabolic imagingMetabolic imagingNon-enhancing tumor regionsBrain tumorsTumor-to-brain contrastTumour-specific valuesActive tumor tissueImage contrastVOI-based analysisGrade 4Evaluate disease progressionTesla MRI scannerFDG-PETGrade 3Lesion gradeTumor tissuesDisease progressionDisease stageOral administrationTumorObservational studyNormal brainContrast enhancement
Academic Achievements & Community Involvement
Copy Link
News
Copy Link
Get In Touch
Copy Link